UNSPSC 51271919: Oxybuprocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C17H28N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VE4U49K15, chemically known as benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci) but more generally known as benoxinate hydrochloride, which bears US NIH Compound Identifier 4633. European Medicines Agency schedules Benoxinate hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03580MIG.

Most nations, for tariff and trade purposes, schedule oxybuprocaine hydrochloride under HS 29225000. SMILES: CCCCOC1CC(CCC1N)C(=O)OCCN(CC)CC.CL.

UNSPSC 51271919 Oxybuprocaine hydrochloride, a Commodity code, encompasses ophthalmic anesthetic products that state and local governments procure through cooperative purchasing agreements for use in healthcare facilities and emergency services. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively building a multi-award pharmaceutical supply contract that includes this product class alongside generic multi-source pharmaceuticals and OTC items for distribution across participating state and local government facilities in Minnesota, Oregon, and other alliance members. State and local healthcare operations—hospitals, clinics, emergency departments, and urgent care centers—drive demand for anesthetics like oxybuprocaine in procurement volumes that flow through established pharmaceutical wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) rather than direct manufacturer-to-end-user channels. The cooperative purchasing model allows participating jurisdictions to leverage pooled buying power and standardized contracts negotiated at the multistate level, reducing administrative overhead for individual agencies.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, seeking manufacturers to supply NDC-coded pharmaceutical products with comprehensive pricing and product data in Excel format. The procurement evaluates vendors on price competitiveness (75 percent weight), fixed pricing stability (10 percent), compliance with cGMP and DSCSA requirements, EDI capability, and administrative-fee structure; awarded vendors will supply products through authorized wholesalers effective July 1, 2026, with products required in the marketplace by May 15, 2026. Vendors must maintain $5 million per-occurrence commercial general liability coverage, $2 million network security and privacy liability, and $2 million professional liability, and agree to a 3 percent administrative fee on all contract purchases with performance penalties of $200 to $1,500 per violation. The contract term runs two years for new vendors with optional extensions, while incumbents align with existing agreements through June 30, 2028; MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. No specific award value, budget range, or set-aside designations appear in the available documentation.